The UK BioIndustry Association (BIA) has called on the government to introduce a new venture capital fund structure that will give the public the opportunity to be partners in the biotech revolution. The BIA argues that many existing venture capital funds are too bureaucratic for the general public and don’t invest in the UK’s growing cohort of innovative biotech companies. The trade association’s proposed fund structure would offer income and capital gains tax reliefs with a minimal-bureaucracy system for claiming, and allow pooling of capital in a diversified portfolio to spread risk. Individuals who stay invested for longer-periods – which is critical for knowledge-intensive companies conducting R&D – will be rewarded with further income tax relief. BIA CEO Steve Bates commented: “The UK has world-leading bioscience companies that are delivering for patients and investors but too few people have the opportunity to share in their financial success. The fund structure we’re proposing will democratize opportunities to share in the success of UK bioscience and provide much-needed long-term capital for the UK’s most innovative companies.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.